Project Grant R01AA033111
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $3.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism awarded The Research Foundation for the State University of New York $2.12 million on August 4, 2026, under the Alcohol Research Programs (CFDA 93.273) to support research into neurobiological factors contributing to tolerance to the adverse consequences of alcohol. The research examines how individuals vary in their sensitivity to the aversive effects of alcohol and how tolerance to these effects develops following repeated alcohol...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Washington University $555,331 on August 13, 2026, under the Alcohol Research Programs (CFDA 93.273) to examine the metabolic-epigenetic regulation of alcohol intake and associated molecular mechanisms. The funded research explores how alcohol-derived acetate generated during alcohol metabolism affects brain histone acetylation and subsequently influences alcohol intake behavior. The project builds on preliminary findings...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), a division of the Department of Health and Human Services National Institutes of Health, awarded Yale University $663,419 on August 11, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate liver sinusoidal endothelial cell (LSEC) inflammation in alcohol-associated liver disease. The research addresses mechanisms by which alcohol disrupts LSEC homeostasis through two converging pathways: IL6 trans-signaling mediated...
- The National Institute on Alcohol Abuse and Alcoholism awarded Cedars-Sinai Medical Center $1.235 million under the Alcohol Research Programs (CFDA 93.273) on September 10, 2025, to investigate the role of prohibitin 1 (PHB1) in ethanol's sensitizing effect on colorectal liver metastasis. Research will examine how excessive alcohol intake depletes hepatocyte nuclear and cytosolic PHB1, increasing matrix metalloproteinase-7 (MMP-7) expression and rendering the liver susceptible to colorectal...
- The National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health within the Department of Health and Human Services, awarded $682,736 to Beth Israel Deaconess Medical Center, Inc. on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate myeloid-derived suppressor cells (MDSCs) in alcohol-associated steatohepatitis. The award funds research characterizing MDSC phenotypes and immunoregulatory capacity in alcohol-associated hepatitis...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Regents of the University of California, San Francisco $613,750 on June 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate brain glucose metabolism dysfunction in alcohol use disorder. The research examines how alcohol activates the mTORC1 signaling pathway in dopamine D1 receptor-expressing neurons within the nucleus accumbens, leading to suppression of glycolytic enzymes including aldolase A and...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Medical University of South Carolina $488,077 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate molecular and functional adaptations in the nucleus reuniens, a midline thalamic region implicated in alcohol-related cognitive deficits. The research addresses how chronic alcohol exposure produces cognitive dysfunction that impairs treatment outcomes and increases relapse risk. The project will...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Trustees of Columbia University in the City of New York $2,359,200 on July 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the regulation of hepatocyte functions by hepatic stellate cells in steatotic liver diseases, including alcohol-associated liver disease, metabolic dysfunction-associated fatty liver disease, and mixed forms. The research characterizes an R-spondin 3-mediated hepatic stellate cell...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $2,072,751 under the Alcohol Research Programs (CFDA 93.273) on September 15, 2025. The recipient is conducting research into innate immune dysregulation in alcohol-associated liver disease, with focus on neutrophil heterogeneity and dysfunction in alcohol-associated hepatitis. The work characterizes transcriptomic profiles and functional roles of neutrophil populations—specifically...
- The National Institute on Alcohol Abuse and Alcoholism awarded Loyola University of Chicago Health Sciences Campus $470,066 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct basic research on the molecular mechanisms by which ABL kinase 2 (ABL2) contributes to alcohol-associated liver disease pathogenesis. The research will investigate three specific areas: the molecular mechanisms by which ABL2 promotes alcohol-induced steatosis; the role of ABL kinases in...